Genetic Testing Market Regional Analysis:
APAC Market Insights
Genetic testing market in Asia Pacific is predicted to account for the largest share of 36% over the analyzed timeframe. The region’s leadership is impelled by the growing healthcare territory and increasing awareness about the benefits of these solutions. Improving accessibility in developing countries, such as India and China, is also presenting a large consumer base for this field. On this note, NLM projected the total number of established healthcare institutions in the mainland China to be 1,030,935 by 2021, backed by the meticulous efforts from the governing bodies. Moreover, habitats in the region are increasingly gaining knowledge about the importance of disease prevention, which is directly bringing greater business flow in this sector.
Several factors are driving the India market, including continuous capital influx, government initiatives, and increased public healthcare expenditure and access to advanced medical facilities. In this regard, IBEF reported that DNA Wellness invested USD 23.9 million to cultivate a nationwide network of over 100 cervical cancer screening labs by 2027, with the rights to offer CERViSure DNA Ploidy Test. Simultaneously, it highlighted the significant increment in cash inflow to the hospitals and diagnostic centres, maintaining an industry value of USD 11.1 billion from 2000 to 2024. This indicates the country’s contribution to a promising future with lucrative opportunities for this sector.
North American Market Insights
The North America genetic testing market is poised to be propagate with a notable pace of growth by the end of 2035. The rising number of technological innovations and well-established healthcare infrastructure in this region is solidifying its progress. As a result of remarkably heightened availability of clinical technology, the advanced testing solutions are being widely adopted and utilized in various disciplines. Moreover, more efficient, cost-effective, and precise genetic insights from these offerings are highly desired for both clinical and academic entities, inspiring companies to invest in this landscape. For instance, in February 2025, Foundation Medicine, in collaboration with Fulgent Genetics, launched two new germline tests, FoundationOneGermline and FoundationOneGermline More, in the U.S. market.
The U.S. is one of the largest contributors in the regional captivity on the global market with improved accessibility and presence of global pioneers. On this note, NLM revealed that the number of newly available genetic tests accounted for 51,803 in 2022, in comparison to 607 in 2012. It also mentioned the estimated size of the U.S. diagnostic testing industry to reach USD 40.1 billion by 2026. Another NLM study concluded the total count of Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories to surpass 320,000 around the country’s territory in 2021. On the other hand, most of the genetic tests originate from and are performed in these CLIA-certified entities, testifying the improved availability in this sector.
